-
Pacritinib, sold
under the
brand name Vonjo, is an anti-cancer
medication used to
treat myelofibrosis. It is a
macrocyclic protein kinase inhibitor. It...
- thrombocythemia)
myelofibrosis (MF). In
March 2022, the FDA
approved pacritinib (Vonjo) with an
indication to
treat adults who have
intermediate or high-risk...
-
Neratinib L01EH03
Tucatinib L01EJ01
Ruxolitinib L01EJ02
Fedratinib L01EJ03
Pacritinib L01EJ04
Momelotinib L01EK01
Axitinib L01EK02
Cediranib L01EK03 Tivozanib...
- the
original on 28
August 2022.
Retrieved 10
September 2022. "Vonjo (
pacritinib) Capsules, for Oral Use. Full
Prescribing Information" (PDF). CTI BioPharma...
- for
clinical use, it is
still used for
research in the area.
Fedratinib Pacritinib Meyer SC,
Keller MD, Chiu S,
Koppikar P,
Guryanova OA,
Rapaport F, et al...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
